Oral Contraceptive Labeling Likely To Become More Graphic
Executive Summary
FDA is nearing completion of guidance on labeling for combined oral contraceptives with an eye toward improving communication with more visual presentations rather than relying on prose.
You may also be interested in...
One-Page MedGuide For Long-acting Opioids Sets Stage For Retooling MedGuide Format
The single-page format could serve as a template as FDA tries to simplify patient information that accompanies prescription drugs.
Blood Clot Risk Of Drospirenone Products Remains Open Issue For FDA
Bayer updates labeling for its drospirenone-containing contraceptives to reflect potentially higher risks compared to other birth control pills as FDA seeks ways to get more definitive information.
FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?
FDA will look at which should come first – benefits or risks – when it studies patients' response to three one-page prototypes of patient medication information.